Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Standard
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. / Roth, Carina; Rack, Brigitte; Müller, Volkmar; Janni, Wolfgang; Pantel, Klaus; Schwarzenbach, Heidi.
in: BREAST CANCER RES, Jahrgang 12, Nr. 6, 6, 2010, S. 90.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
AU - Roth, Carina
AU - Rack, Brigitte
AU - Müller, Volkmar
AU - Janni, Wolfgang
AU - Pantel, Klaus
AU - Schwarzenbach, Heidi
PY - 2010
Y1 - 2010
N2 - ABSTRACT : INTRODUCTION : MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for the first time, the feasibility and clinical utility of circulating miRs as biomarkers for the detection and staging of breast cancer. METHODS : The relative concentrations of breast cancer-associated miR10b, miR34a, miR141 and miR155 were measured in the blood serum of 89 patients with primary breast cancer (M0, n = 59) and metastatic disease (M1, n = 30), and 29 healthy women by a TaqMan MicroRNA Assay. RESULTS : The relative concentrations of total RNA (P = 0.0001) and miR155 (P = 0.0001) in serum significantly discriminated M0-patients from healthy women, whereas miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P = 0.008) discriminated M1-patients from healthy controls. In breast cancer patients, the changes in the levels of total RNA (P = 0.0001), miR10b (P = 0.01), miR34a (P = 0.003) and miR155 (P = 0.002) correlated with the presence of overt metastases. Within the M0-cohort, patients at advanced tumor stages (pT3 to 4) had significantly more total RNA (P = 0.0001) and miR34a (P = 0.01) in their blood than patients at early tumor stages (pT1 to 2). CONCLUSIONS : This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the blood of breast cancer patients and associated with tumor progression.
AB - ABSTRACT : INTRODUCTION : MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for the first time, the feasibility and clinical utility of circulating miRs as biomarkers for the detection and staging of breast cancer. METHODS : The relative concentrations of breast cancer-associated miR10b, miR34a, miR141 and miR155 were measured in the blood serum of 89 patients with primary breast cancer (M0, n = 59) and metastatic disease (M1, n = 30), and 29 healthy women by a TaqMan MicroRNA Assay. RESULTS : The relative concentrations of total RNA (P = 0.0001) and miR155 (P = 0.0001) in serum significantly discriminated M0-patients from healthy women, whereas miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P = 0.008) discriminated M1-patients from healthy controls. In breast cancer patients, the changes in the levels of total RNA (P = 0.0001), miR10b (P = 0.01), miR34a (P = 0.003) and miR155 (P = 0.002) correlated with the presence of overt metastases. Within the M0-cohort, patients at advanced tumor stages (pT3 to 4) had significantly more total RNA (P = 0.0001) and miR34a (P = 0.01) in their blood than patients at early tumor stages (pT1 to 2). CONCLUSIONS : This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the blood of breast cancer patients and associated with tumor progression.
U2 - 10.1186/bcr2766
DO - 10.1186/bcr2766
M3 - SCORING: Zeitschriftenaufsatz
VL - 12
SP - 90
JO - BREAST CANCER RES
JF - BREAST CANCER RES
SN - 1465-5411
IS - 6
M1 - 6
ER -
